Abstract
Overview
Introduction
In 2007, HIV drugs achieved sales of $9.3 billion in the 7MM, growing faster
than the overall market at a CAGR of 11.3% from 2004-2007. Due to patent
expirations, Datamonitor expects the market' s growth to slow down somewhat,
reaching total sales of $15.1 billion in 2017. Among the ROW, the Canadian HIV
market in 2007 was worth $272 million, achieving a CAGR of 24% from 2004-2007.
Scope
- In-depth analysis of the current HIV market across the US, EU, Japan and a
ROW snapshot
- Thorough assessment of underlying commercial and clinical factors shaping
the antiretroviral market
- Detailed sales forecasts for the major antiretroviral classes, molecules
and brands in each of the seven major markets
- Case study analysis of the Canadian market including an in-depth
assessment of the healthcare system and potential opportunities and threats
Highlights
Gilead is now the market leader in HIV with a portfolio of just four marketed
products. Datamonitor expects JnJ/Tibotec and Merck to be the fastest growing
companies over the next 10 years. While Tibotec only entered the field with
the launch of its first product in 2006, Merck & Co.' s first-in-class
Isentress reenergized its HIV efforts in 2007.
The HIV market is very concentrated, with the top 10 brands accounting for 80%
of total antiretroviral sales across the 7MM in 2007. Truvada was the
bestselling drug with revenues of $1.5 billion. Gilead and BMS' rapidly
growing joint venture Atripla was already the fourth best selling HIV drug
despite the absence of ex-US sales during the period.
While the 7MM and Canada are commercially the most significant for HIV,
companies are now turning towards fast-growing emerging markets as new sources
of revenue growth. The potential is there: the 7MM only account for 36% of the
globally infected population, but more than 85% of revenues.
Reasons to Purchase
- Understand the changing market dynamics of HIV drugs, key success factors
for leading brands as well as the impact of pending patent expiries
- Understand the patient acquisition process with key inflection points in
the decision-making process to choose antiretroviral drug brands
- Obtain full global, country, class and product-specific forecasts of
currently marketed and pipeline antiretrovirals from 2007 to 2017
| 
View Cart
